Tal1 Polyklonale Antilichaam, FITC Vervoeging

Activation of TAL1 characterizes up to 60% of cases of human T cell acute lymphoblastic leukemia, making it the most frequent gain-of-function mutation observed in this disorder. TAL1 (also designated SCL) is a serine phosphoprotein and basic helix-loop-helix transcription factor known to regulate embryonic hematopoiesis. This transcription factor binds as a heterodimer with E2A and HEB/HTF4 to a nucleotide sequence motif termed the E-box. In addition, leukemogenesis is accelerated dramatically by transgenic co-expression of TAL1 and the catalytic subunit of casein kinase IIalpha, a serine/ threonine protein kinase known to modulate the activity of other bHLH transcription factors.

BHLHa17; Class A basic helix-loop-helix protein 17; SCL antibody; Stem cell protein; T cell acute lymphocytic leukemia 1; T cell acute lymphocytic leukemia 1 protein; T cell leukemia/lymphoma 5 protein; T-cell acute lymphocytic leukemia protein 1; T-cell leukemia/lymphoma protein 5; Tal 1; Tal 1 product; TAL 1 protein; TAL-1; tal1; TAL1_HUMAN; TCL 5; TCL5.

Human, Mouse, Rat

185-300/331

Tal1

FITC

KLH conjugated synthetic peptide derived from human Tal1

IF

Purified by Protein A.

494nm/518nm

1µg/µl

IF (IF=1:50-200)

Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Unmodified

Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.